Xeris Biopharma Holdings, Inc.

US$15.20As of Sun 8 Nov 2026, 12:00 UTC
NASDAQ:XERSHealthcare
Country USA
PE (Fwd) •••
TSR 5Y CAGR 51.95%
Div yield —
ROE (27.11%)
Drug Manufacturers (Specialty & Generic)
Beta (5Y) 0.84
PE TTM —
TSR TTM 56.70%
Mkt cap US$2.777B
ROIC 11.00%
SE Grade™
Value
Quality
Moat
Consensus
Reference
$15
1.48%
(40.83%)
Sell 1|9|6|6|9
4Q25
1Q26
2Q26
3Q26
Earnings per share$
0.20
0.21
0.23
0.25
18.43%
17.64%
19.89%
21.44%
Revenue$M
124.9
129.3
134.2
139.6
2.47%
5.67%
7.25%
10.88%
Peers (US$2.777B)
Cap (US$)
PE
2.037B
13.23x
Capital
TTM
5Y
10Y
Leveragex
0.434
0.778
0.683
EBIT/Intx
1.486
0.430
0.351
Own earn%
(28.11)
57.58
57.69
Sh yield%
19.81
35.28
34.62
Owners
Insiders/Inst%
9.71
38.62
Short interest%
5.52
SBC / revenue%
1.05
Record
10Y
Profitable years
10/10
Revenue growth years
10/10
EPS growth years
10/10
Dividend streakyrs
9
Op margin range%
29–35
$1 testx
—
Incr. ROIC%
13